Skip to main
SRZN
SRZN logo

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen Inc. is advancing its innovative preclinical programs that focus on the modulation of the Wnt pathway, which has demonstrated the potential to stimulate retinal vessel regrowth and suppress pathological vessel growth. The company's exploration of the FZD4 lipoprotein receptor-related protein as a bi-specific antibody for targeting Wnt signaling in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) suggests a strong market position in ophthalmology. Overall, these clinical advancements, combined with a robust internal Wnt platform, provide a promising foundation for the company's future growth and value creation.

Bears say

Surrozen Inc. faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its developmental candidates to meet peak commercial revenue estimates, which could be influenced by market size and pricing dynamics. Additionally, the company reported a substantial net loss of $27.0 million, or $7.43 per diluted share, for the first quarter of fiscal year 2025, indicating ongoing financial strain. Lastly, challenges related to securing necessary capital resources to fund operations further compound the uncertainties surrounding continued program development and commercialization efforts.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.